Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Announcement under Regulation 30 (LODR)-Press Release / Media Release

 We hereby inform that as per the USFDA letter with reference to the company's supplemental abbreviated new drug application (sANDA) received for review on August 20, 2018, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C; Act) for Ranitidine Injection USP, 25 mg/mL, 2 mL Single dose vials and 6 mL Multi-dose vials, the sANDA approval has been granted by the USFDA for a new fill size, 40 mL Pharmacy Bulk Package...
12-12-2018
Bigul

Cadila Healthcare arm gets USFDA nod for ulcer treatment injection

 New Delhi, December 11 Cadila Healthcare arm has received approval from the US health regulator to market Ranitidine injection, used to treat stomach
11-12-2018
Bigul

Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Liva Pharmaceuticals receives approval from the USFDA for its supplemental abbreviated new drug application (sANDA), Ranitidine Injection USP
11-12-2018
Bigul

Announcement under Regulation 30 (LODR)-Change in Directorate

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular dated September 9, 2015, we hereby inform that upon the recommendation of the Nomination and Remuneration Committee, the Board of Directors at their meeting held today i.e. December 6, 2018 passed a resolution approving the appointment of Mr. Bhadresh Shah (DIN: 00058177) as an Additional Independent Director subject to...
06-12-2018
Bigul

Cadila Healthcare Limited (The 'Company') Has Entered Into A Share Subscription Agreement ('SSA') With Zydus Wellness Limited (ZWL), A Subsidiary Company, To Subscribe To 85,02,170 Equity Shares At An Issue Price Of Rs. 1,382/- (Face Value Per Equity Share Of Rs. 10/- Each And Premium Of Rs. 1,372/-) Amounting To Rs. 11,74,99,98,940/- In Accordance With The Requirements Of Securities And Exchange Board Of India (Issue Of Capital And Disclosure Requirements) Regulations, 2018 ('SEBI ICDR Regulations') And Such Other Acts / Rules / Regulations As May Be Applicable (Each As Amended), Subject To Approval Of The Members Of ZWL.

 Cadila Healthcare Limited (the 'Company') has entered into a share subscription agreement ('SSA') with Zydus Wellness Limited (ZWL), a subsidiary Company, to subscribe to 85,02,170 equity shares at an issue price of Rs. 1,382/- (face value per equity share of Rs. 10/- each and premium of Rs. 1,372/-) amounting to Rs. 11,74,99,98,940/- in accordance with the requirements of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements)...
06-12-2018
Bigul

Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Zydus receives final approvals from the USFDA for Teriflunomide Tablets.
01-12-2018
Bigul

Broker's call: Cadila Healthcare (Buy)

 Reliance SecuritiesCadila Healthcare (Buy)CMP: 363.9Target: 450Cadila Healthcare is an Indian pharmaceutical company headquartered at Ahmedabad in G
30-11-2018
Bigul

Zydus Cadila gets USFDA nod to market generic Lansoprazole tablets

 Zydus Cadila has received final nod from the US health regulator to market generic Lansoprazole delayed release orally disintegrating tablets in the s
29-11-2018
Bigul

Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Zydus receives approvals from the USFDA for Lansoprazole Tablets and Linagliptin tablets
29-11-2018
Bigul

Zydus Cadila gets USFDA nod for generic muscle spasm treatment tablets

 The tablets will be manufactured at the group's formulations manufacturing facility at Baddi.
27-11-2018
Next Page
Close

Let's Open Free Demat Account